<!DOCTYPE html>
<html>
<head>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" type="text/css" href="css/style-manual.css">
    <link rel="stylesheet" href="https://www.w3schools.com/w3css/4/w3.css">
    <script src="js/script.js"></script>
</head>
<body>
        <!--Vontac-------------------------------------------------------->
	<div class="bodyDiv" id="idVontac">
    <div class="w3-container w3-center w3-animate-left">
        <h2 class="mango">Vontac</h2>
    </div>
<b>Product Orientation & Presentation:</b><br> 
<table class="table1">
<tr>
    <td><b>Brand Name:
	</b><br>
    Vontac
	</td>
</tr>

<tr>
    <td><b>Generic & Strength:
	</b><br>
	Vonoprazan INN 10 mg & 20 mg Tablet
	</td>
</tr>
  
 <tr>
     <td>
	<b>Dosage Form:
	</b><br>Tablet
	 </td>
</tr>
	 
<tr>
    <td><b>Therapeutic Class:
	</b><br>
	--
	</td>
</tr>
 
<tr>
    <td><b>Sub Therapeutic class:
	</b><br>
	--
	</td>
</tr>
		 
<tr>
    <td><b>Commercial Pack:
	</b><br>
	×
	</td>
</tr>
	 
<tr>
    <td>
    <b>Price (TP):
	</b><br>
	Vontac 10mg: 7.00 Bdt/ Cap<br>
 Vontac 20mg: 10 Bdt/ Cap.
	
    </td>
</tr>	
	 
<tr>
    <td><b>Flavour:
	</b><br>
	--
	</td>
</tr>
  
<tr>
    <td><b>Indication:
	</b><br>
	Treatment of<br><br>
gastric ulcer,<br>
	duodenal ulcer,<br>
	reflux esophagitis;<br><br>
	
	prevention of recurrent gastric or duodenal ulcer associated with low-dose aspirin administration; and<br>
	prevention of recurrent gastric or duodenal ulcer associated with non-steroidal anti-inflammatory drug administration.<br><br>
	
	Adjunct therapy to Helicobacter pylori eradication in the following: Gastric or duodenal ulcer, Gastric Mucosa Associated Lymphoid Tissue (MALT) lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early-stage gastric cancer, or Helicobacter pylori gastritis.
	</td>
</tr>
  
<tr>
    <td><b>Pregnancy:
	</b><br>
	Vonoprazan should be used in pregnant women or women having possibilities of being pregnant only if the expected therapeutic benefit is thought to outweigh any possible risk.  
    </td>
</tr>

<tr>
    <td><b>Lactation:
	</b><br>
	It is advisable to avoid the administration of Vonoprazan to nursing mothers. However, when the administration is indispensable, nursing should be discontinued.
    </td>
</tr>

<tr>
    <td><b>Children:
	</b><br>
	Vonoprazan has not been studied in patients under 18 years of age.
    </td>
</tr>
  
<tr>
    <td><b>Brand Name Justification:
	</b><br>
---	
	</td>
</tr>

<tr>
    <td><b>Brand Slogan:
	</b><br>
	Simply better than Esomeprazole
    </td>
</tr>

<tr>
    <td><b>Dosage & Administration:
	</b><br>
<b>&#x2022; Gastric ulcer:</b><br> 
The usual adult dosage is 20 mg once daily, 8 weeks.<br> 
  <b>&#x2022; Duodenal ulcer:</b><br> 	
  The usual adult dosage is 20 mg once daily, 6 weeks.<br> 

  <b>&#x2022; Reflux esophagitis:</b><br> 
The usual adult dose is 20 mg once daily for a total of 4 weeks of treatment.<br>
If that dosing proves insufficient, the administration should be extended, but for no longer than 8 weeks of treatment. <br> 
For the maintenance therapy of reflux esophagitis showing recurrence. The dose is 10 mg once daily. <br> 
When the efficacy is inadequate, the dosage may be increased up to 20 mg once daily. <br> 

&#x2022; Prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin administration:<br> 
The usual adult dose is 10 mg once daily.<br> 

&#x2022; Prevention of recurrence of gastric or duodenal ulcer during non-steroidal anti-inflammatory drug (NSAID) administration:<br>
The usual adult dose is 10 mg once daily.<br> 

&#x2022; Adjunct to Helicobacter pylori eradication:<br> 
For adults, the following three-drug regimen should be administered orally at the same time twice daily for seven days: 20 mg dose of Vonoprazan, 750 mg dose of amoxicillin hydrate and 200 mg dose of clarithromycin.<br> 
If Helicobacter pylori eradication with a three-drug regimen comprising a proton pump inhibitor, amoxicillin hydrate and clarithromycin has been unsuccessful, as an alternative treatment, adults should be administered the following three drugs twice daily for seven days: 20 mg of Vonoprazan, 750 mg of amoxicillin hydrate and 250 mg of Metronidazole or as directed by the physicians.
    </td>
</tr>

<tr>
    <td><b>Key Selling Points::
	</b><br>
&#x2022; Provides rapid and longer action with distinct mechanism<br>
&#x2022; The best alternative to treat hyperacidity & acid-related disorders<br>  
&#x2022; Better than Esomeprazole  
<br><br>
&#x2022; Provides rapid and longer action with distinct mechanism<br>
&#x2022; The best alternative to treat hyperacidity & acid-related disorders<br>
&#x2022; Truely once daily dose
    </td>
</tr>

<tr>
    <td><b>Target Doctor:
	</b><br>
	---
&#x2022; <br>
    </td>
</tr>

<tr>
    <td><b>Side effects:
	</b><br>
	--
&#x2022; 
    </td>
</tr>

<tr>
    <td colspan="4">
<b>Mode of action:</b><br>	
Different mode of action ensures proper acid control<br>
<table class="table2">
<thead>
    <tr>
       <th>
	   Vonoprazan<br>

(Potassium-competitive acid blockers)
       </th>
       <th>
       </th>
    </tr>
</thead>

<tbody>
    <tr>
       <td><b>&#8681;</b>
	   </td>
       <td>
	   </td>
    </tr>
	<tr>
       <td>Binds reversibly to the Potassium binding site of H<sup>+</sup>, K<sup>+</sup> ATPase(proton pumps)
	   </td>
       <td>
	   </td>
    </tr>
	<tr>
       <td><b>&#8681;</b>
	   </td>
       <td>
	   </td>
    </tr>
	<tr>
       <td>Inhibit the Exchange of H<sup>+</sup> & K<sup>+</sup> ATPase enzyme<b>&#8680;</b>
	   </td>
       <td>Blocks K<sup>+</sup> movement to parietal cell.<br> Inhibits H<sup>+</sup> release from parietal cell.
	   </td>
    </tr>
	<tr>
       <td><b>&#8681;</b>
	   </td>
       <td>
	   </td>
    </tr>
	<tr>
       <td>Controls acidity
	   </td>
       <td>
	   </td>
    </tr>
</tbody>
</table>
<br> 


    </td>
</tr>
</table>
<br><br>



<b>Gastric Acid Treatment Redefined</b>

<b>Revolutionization in the management of acid control:</b><br>

Calcium carbonate Sodium bicarbonate: Antacids introduced in 1930s<br>

Ranitidine, Cimetidine, Famotidine: H<sub>2</sub> Antagonists introduced in 1970s<br>

Conventional PPIs: PPIs introduced in 1989s<br>

<b>Vonoprazan:</b>Potassium-competitive acid blockers introduced in 2015s<br><br>

For the treatment of acid-related diseases, the use of antacids & H<sub>2</sub> Antagonists has turned to dust due to the short duration of efficacy. PPIs, especially Esomeprazole once took the place of antacids and H<sub>2</sub> antagonists despite having several limitations like -<br>

1. Slow onset of action<br>
2. Food dependent<br>
3. Unstable in acidic conditions<br>
4. Short half-life<br>
5.Irreversible binding to proton pumps<br>
6. Unsatisfactory effects at night<br><br>

But Vonoprazan is the new horizon of acid control that overcomes conventional PPIs' limitations -<br>
1. Faster onset of action<br>
2. Food-independent<br>
3. Stable in acidic conditions<br>
4. Longer half-life<br>
5. Reversible binding with proton pumps<br>
6. Maintains a prolonged & consistent acid control<br><br>



<b>Better pharmacokinetics than PPIs:</b><br><br>

<b>400 times more efficacious, better response than PPIs</b><br>
Vonoprazan<b>&#8680;</b> requires only <b>2 hours</b> of a single dose<b>&#8680;</b>to achieve <b>24-hours</b> acid suppression<br>
BUT<br>
PPIs<b>&#8680;</b> need <b>3 to 5 days</b><b>&#8680;</b> to achieve stable acid suppression<br><br>


<b>Higher concentration in the parietal cells ensures rapid onset of action</b><br>
	
Vonoprazan with Higher pKa, <b>9.06</b> <b>&#8680;</b> concentration at intracellular canaliculi is 10,0000,000(10 Cror)fold higher than in the blood <b>&#8680;</b> <b>Acts faster than PPIs</b><br>

BUT<br>

PPIs with low pka, around <b>4</b><br>

concentration at intracellular canaliculi is <b>1,000 fold</b> higher than in the blood<br>

<b>acts slowly</b><br><br>


<b>Longer half-life and longer action than PPls</b><br>
Vonoprazan <b>&#8680;</b> <b>9 hours</b> half-life <b>&#8680;</b> dissociates slowly from the proton pumps <b>&#8680;</b> 
<b>longer duration of action</b><br>

BUT<br>
PPIs <b>&#8680;</b> Half life less than <b>2 hours</b> <b>&#8680;</b> <b>shorter duration of action</b><br>
(Canaliculus plural canaliculi, a minute canal in a bodily structure. In anatomy- a canaliculus is a small passageway.
gastric parietal cells- A canaliculus is an adaptation found on gastric parietal cells. It is a deep infolding, or little channel, which serves to increase the surface area, e.g. for secretion.)<br><br>

<b>Better than Esomeprazole</b><br><br>
	
<b>Longer half life, longer acid suppression than Esomeprazole</b><br>
The half-life of Vonoprazan is around <b>9 hours</b><br>
whereas<br>
Esomeprazole is <b>1.3 hours</b><br>
As a result Vonoprazan ensures longer acid suppression than Esomeprazole.<br><br>

<b>More profound and quicker acid control than Esomeprazole</b><br><br>
	
<b>Improved Time Above pH 4.0</b><br>
Vonoprazan 20 mg<br>
Baseline&#x261E; 11%<br>
%Day 1&#x261E; 71%<br>
%Day 7&#x261E; 86%<br>

Esomeprazole 20 mg<br>
Baseline&#x261E; 11%<br>
%Day 1&#x261E; 24%<br>
%Day 7&#x261E; 61%<br><br>


<b>Superior to Esomeprazole to treat post-ESD* ulcer</b><br>
No. of patients: 92<br>
Duration: 8 weeks<br>
Ulcer Improvement rate<br>
Vonoprazan 20 mg&#x261E; 95%<br>
Esomeprazole 20 mg&#x261E; 78%<br>

Result: Vonoprazan ensures better Ulcer treatment than Esomeprazole.<br>
ESD: Endoscopic Submucosal Dissection.<br><br>

	

<b>Clinical excellence</b><br><br>
	
<b>Shows excellent healing rate of erosive esophagitis</b><br>
Drug: Vonoprazan 20 mg<br>
No. of patients: 401<br>
Healing rate %<br>
Week-2&#x261E; 91%<br>

Week-4&#x261E; 97%<br>

Week-8&#x261E; 99%<br>
Result: Vonoprazan heals almost <b>100%</b> of erosive esophagitis<br>
Helps Maintain quality of life<br><br>



<b>Offers excellent day-time and night-time acid control</b><br>
Patients with complete symptom relief, %<br>
Day-time heartburn relief<br>
Vonoprazan 20 mg<br>
Day-1<br>
80%<br>
Night-time heartburn relief<br>
Vonoprazan 20 mg<br>
Day-1<br>
80%<br>
<b>Confirms 24-hr acid control</b><br><br>


<b>Obtains better H. pylori eradication</b><br>
H.pylori eradication rate<br>
Vonoprazan + Amoxicillin + Clarithromycin&#x261E; 96%<br>
PPI + Amoxicillin + Clarithromycin&#x261E; 70%<br>
Journal of Gastroenterology and Hepatology Foundation.<br>
Seven-day Vonoprazan-based triple therapy with high-dose Amoxicillin is a potential first-line anti- H. pylori regimen alternative to the current standard treatment.<br>
<b>Confirms H. pylori-free healthy stomach</b><br><br>


<b>Bangla Detailing Talk:</b><br>
স্যার, প্রায় প্রতিদিনই আপনার কাছে hyperacidity problem নিয়ে অনেক patient আসে। এই hyperacidity চিকিৎসা
আপনারা বহুদিন ধরে PPI prescribe করছেন। যদিও এইসব PPI এর রয়েছে বেশ কিছু limitations. যেমন, Slow onset of action and shortest action, food dependency and unsatisfactory effect at night. স্যার, PPI এর এই limitation overcome করতে Navana Pharma প্রথম বারের মত launch করেছে Vontac, a preparation of Vonoprazan (ভোনোপ্লাজান)। Vontac (Vonoprazan) একটি P-CAB (পটাসিয়াম কম্পিটিটিভ অ্যাসিড ব্লকার) যা hyperacidity চিকিৎসায় নির্দেশিত।<br>

স্যার, Vonoprazan, proton pump এর potassium binding site এ bind করে হাইড্রোজেন (H<sup>+</sup>) এবং potassium
(K<sup>+</sup>) এর exchange এ বাধা দেয় এবং এসিড নিঃস্বরণ নিয়ন্ত্রণ করে ।<br>

স্যার, ক্লিনিক্যাল ট্রায়াল এ দেখা গিয়েছে যে-<br>

• Vontac (Vonoprazan) conventional PPI থেকে 400 time more efficacy নিশ্চিত করে এবং  truly
once daily dose এ কার্যকর।<br>

• স্যার, Vontac (Vonoprazan) এর high PK<sup>A</sup> (9.6) হওয়ায় এর parictal cell এ concentration blood থেকে 10 Cr. fold বেশি হয়, তাই Vontac (Vonoprazan) PPI এর তুলনায় rapid কাজ করে।<br>
	
• Vontac (Vonoprazan) 1st single dose এ maximum ২৪ ঘন্টা ব্যাপী hyperacidity control করে, যেখানে optimum efficacy পেতে PPI গুলোর ৩ থেকে ৫ দিন লাগে ।<br>

• Vontac (Vonoprazan) এর half life 9 hr, যেখানে PPI এর half life less than 2 hour. তাই Vontac (Vonoprazan) PPI গুলোর তুলনায় longer action দেয় ।<br>

• Vontac (Vonoprazan) Esomeprazole থেকে better, কারণ Vonoprazan এর half life Esomeprazole
থেকে অনেক বেশি তাই Esomeprazole থেকে অনেক বেশি সময় ধরে কাজ করতে পারে এবং P<sup>H</sup> Esomeprazole থেকে বেশি সময় 4 এর উপরে রাখে।<br>

• Vontac (Vonoprazan) erosive esophagitis এ almost 100% efficacy ensure করে।<br>

• According to Journal of Gastroenterology and Hepatology, Vonoprazan, conventional
triple এর alternative হিসেবে 
1<sup>st</sup> line anti H. Pylori regimen হিসেবে ব্যবহার করা যাবে high dose Amoxicillin & Clarithromycin সাথে।<br>

• Vontac (Vonoprazan) truly once daily যা খাবারের আগে বা পরে যে কোনও সময় খাওয়া যায়।<br>

• স্যার, Vontac (Vonoprazan) এর benefits consider করে hyperacidity চিকিৎসায় আপনার কাছ থেকে Vontac এর দৈনিক ৫টি প্রেসক্রিপশন আশা করছি।<br><br>
  


<b>Frequently Asked Questions ( FAQ )</b><br>

<b>1. How is Vonoprazan better than PPI ?</b><br>

Ans : 
PPIs have some limitations such as slow onset of action , shortest action , food dependency , and unsatisfactory effect at night but Vonoprazan ensures faster & longer action and 24 - hour acid control . It is food - independent . Vonoprazan controls Acidity by a single dose but PPI needs 3 to 5 days . That's why Vonoprazan is better than PPIs .
<br>
<b>2. How does Vonoprazan ensure faster action ?</b><br>

Ans : 
Vonoprazan is an active drug . It can start its action within the shortest possible time . Its concentration in the parietal is 10 Cr . fold higher than the blood . That's why Vonoprazan ensures faster action .
<br>
<b>3. Why does Vonoprazan ensure a longer duration of action ?</b><br>

Ans : 
The half - life of Vonoprazan is around 9 hours . Due to the higher half - life , Vonoprazan ensures a longer duration of action .<br>

<b>4. How does Vontac is better option for erosive esophagitis ?
</b><br>
Ans : 
Vontac ensures almost 100 % efficacy in erosive esophagitis . That's why Vontac is the better treatment option for erosive esophagitis .<br>

<b>5. How is Vonoprazan better than Esomeprazole ?
</b><br>
Ans : 
Half - life of Vonoprazan ( 9 hr . ) is higher than Eomeorazole ( 1.3 hr . ) . It maintains better intragastric pH than Esomeprazole . That's why Vonoprazan is better than Esomeorazole .<br>

<b>6. Can Vonoprazan be used for triple therapy ?
</b><br>
Ans : 
According to the Journal of Gastroenterology and Hepatology , Vonoprazan is the alternative therapy to conventional triple therapy with high - dose amoxicillin & Clarithromycin .
<br><br>


<b>Composition:</b><br> 
Vontac 10:<br> 
Each film coated tablet contains Vonoprazan fumarate INN equivalent to Vonoprazan 10 mg.<br> 
Vontac 20:<br> 
Each film coated tablet contains Vonoprazan fumarate INN equivalent to Vonoprazan 20 mg.<br> 

<b>Pharmacology:</b><br> 
Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) that works through a reversible potassium-specific competitive mechanism to inhibit active proton pumps directly. Vonoprazan does not require acid activation or any time constraints for its administration. As a result of its rapid onset and prolonged action, Vonoprazan is a suitable option for PPI. Vonoprazan can be taken regardless of meal ingestion and the rate of absorption is not affected by meals. The absorption speed of Vonoprazan is rapid, and the time taken to reach maximum concentration in plasma is less than 2 hours after oral administration. After absorption, the T1/2 in plasma is approximately 2 hours for conventional PPIs, but up to 9 hours for vonoprazan. Therefore, Vonoprazan stays in the blood longer and can block acid secretion continuously.<br> 

<b>Indication:</b><br> 
Treatment of gastric ulcer, duodenal ulcer, reflux esophagitis; prevention of recurrent gastric or duodenal ulcer associated with low-dose aspirin administration; and prevention of recurrent gastric or duodenal ulcer associated with non-steroidal anti-inflammatory drug administration. Adjunct therapy to Helicobacter pylori eradication in the following: Gastric or duodenal ulcer, Gastric Mucosa Associated Lymphoid Tissue (MALT) lymphoma, idiopathic thrombocytopenic purpura, the stomach after endoscopic resection of early-stage gastric cancer, or Helicobacter pylori gastritis.<br>  

<b>Dosage & Administration:</b><br> 
Gastric ulcer & duodenal ulcer:<br> 
The usual adult dosage is 20 mg once daily, 8 week treatment for gastric ulcer and a 6-week treatment for duodenal ulcer.<br> 

Reflux esophagitis:<br> 
The usual adult dose is 20 mg once daily for a total of 4 weeks of treatment. If that dosing proves insufficient, the administration should be extended, but for no longer than 8 weeks of treatment. For the maintenance therapy of reflux esophagitis showing recurrence. The dose is 10 mg once daily. When the efficacy is inadequate, the dosage may be increased up to 20 mg once daily. <br> 

Prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin administration:<br> 
The usual adult dose is 10 mg once daily.<br> 

Prevention of recurrence of gastric or duodenal ulcer during non-steroidal anti-inflammatory drug (NSAID) administration:<br>
The usual adult dose is 10 mg once daily.<br> 

Adjunct to Helicobacter pylori eradication:<br> 
For adults, the following three-drug regimen should be administered orally at the same time twice daily for seven days: 20 mg dose of Vonoprazan, 750 mg dose of amoxicillin hydrate and 200 mg dose of clarithromycin. If Helicobacter pylori eradication with a three-drug regimen comprising a proton pump inhibitor, amoxicillin hydrate and clarithromycin has been unsuccessful, as an alternative treatment, adults should be administered the following three drugs twice daily for seven days: 20 mg of Vonoprazan, 750 mg of amoxicillin hydrate and 250 mg of Metronidazole or as directed by the physicians.<br> 

<b>Contraindications:</b><br>
Contraindicated in patients with hypersensitivity to Vonoprazan or any of the excipients and acute asthma attack.<br>

<b>Warnings & Precautions:</b><br>
During treatment, the patients should closely be observed and the minimum therapeutic necessity should be used according to the disease condition. In the maintenance of healing of reflux esophagitis, Vonoprazan should be administered only to the patients who repeat recurrence and recrudescence of the condition. When the healing is maintained over a long period and when there is no risk of recurrence, the dose reduction to a dose of 10 mg from a dose 20 mg or stop taking medication.<br> 

<b>Side Effects:</b><br> 
Following side effects have been reported with the use of Vonoprazan: Diarrhea, constipation, drug hypersensitivity (including anaphylactic shock), urticaria, hepatotoxicity, jaundice, rash, nausea, abdominal distension, gamma-glutamyltransferase increased, AST increased, Liver function test abnormal, ALT increased, ALP increased, LDH increased, &#947; - GPT increased,
edema and eosinophilia.<br>  

<b>Use in Pregnancy & Lactation:</b><br> 
Vonoprazan should be used in pregnant women or women having possibilities of being pregnant only if the expected therapeutic benefit is thought to outweigh any possible risk. It is advisable to avoid the administration of Vonoprazan to nursing mothers. However, when the administration is indispensable, nursing should be discontinued.<br>  

<b>Use in Children & Adolescents:</b><br> 
Vonoprazan has not been studied in patients under 18 years of age.<br>  

<b>Drug Interaction:</b><br> 
Vonoprazan should be administered with care when co-administered with the following drugs: CYP3A4 inhibitors, Clarithromycin etc. may increase the blood concentration of Vonoprazan. Use of Digoxin, Methyldigoxin with Vonoprazan may enhance the efficacy of Digoxin and Methyldigoxin.<br>  

<b>Overdosage:</b><br> 
There is no evidence of overdose with Vonoprazan. Vonoprazan is not removed from the circulation by hemodialysis. If overdose occurs, treatment should be symptomatic and supportive.<br> 

<b>Storage:</b><br> 
Store below 30°C, keep away from light and in a dry place. Keep all medicines out of the reach of children.<br> 

<b>Packing:</b><br> 
Vontac 10: Each box contains 3X10 tablets in alu-alu blister pack and an insert. Vontac 20: Each box contains 3X10 tablets in alu-alu blister pack and an insert.<br> <br> 
</div>
<footer>
    <p>© 2024 Md. Nurullah. All rights reserved.</p>
</footer>
<center><div class="ovalEnd">The End-Vontac</div></center><!--End Line---->
</body>
</html>